| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total revenues | 875 | 81 | 194 | |
| Research and development | 348 | 36 | 81 | |
| General and administrative | 1,533 | 1,502 | 1,241 | |
| Total cost and expenses | 1,881 | 1,538 | 1,322 | |
| Loss from operations | -1,006 | -1,457 | -1,128 | |
| Interest income | 30 | - | 42 | |
| Gain from settlement of account payable | 0 | - | 363 | |
| Gain from insurance recovery | 0 | - | - | |
| Total other income, net | 30 | - | 405 | |
| Net loss from continuing operations | - | - | -723 | |
| Net loss | -976 | - | -723 | |
| Foreign currency translation adjustment loss | 0 | - | - | |
| Comprehensive loss | -976 | - | - | |
| Earnings per share, diluted | -0.3 | -0.56 | -0.29 | |
| Net loss per share - basic | -0.3 | -0.56 | -0.29 | |
| Weighted average shares used in calculating net loss per share - basic | 3,225,000 | 2,556,000 | 2,526,000 | |
| Weighted average shares used in calculating net loss per share - diluted | 3,225,000 | 2,556,000 | 2,526,000 | |
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)